Medical Devices Startups

MR3 Health is a remote patient monitoring (RPM) company combining service and medical technology, including its proprietary FDA-cleared TempTouch device, to help physicians, podiatrists and clinical teams manage chronic conditions like hypertension and diabetes. It monitors patients daily to detect abnormal physiologic trends and alerts providers so they can intervene before acute health events occur.

0 investors

Myocardial Solutions develops MyoStrain, a cardiac MRI technology that measures regional heart function for clinical and research use. The company serves healthcare institutions and medical professionals in the cardiology and imaging sectors.

0 investors

MYOLYN develops Functional Electrical Stimulation (FES) technology that helps users activate muscles, build strength, and improve movement. Its systems serve people with paralysis, rehabilitation patients, active adults, and athletes across home, clinical, and training settings.

0 investors

Nabsys develops genome mapping technology for genomic structural variant analysis, enabling precision and cost-effectiveness in this field. The company serves research and clinical customers globally.

0 investors

Namida is an early cancer detection company. The referenced page is a biography of an advisory board member rather than a description of the company's products.

0 investors

NanoGuard Technologies is a deep-technology company developing High Voltage Atmospheric Cold Plasma treatment technology and its applications. It works across scientific, technical, and commercial disciplines to evaluate application needs based on data.

0 investors

Nanoscope Therapeutics develops therapies for patients with complex retinal diseases that have high unmet need, including inherited retinal degenerations. The company focuses on treatments aimed at restoring vision in people affected by retinal blindness.

0 investors

Nanowear develops an FDA-approved, cloth-based nanotechnology undergarment with embedded nanosensors that capture 85+ medical-grade biomarkers, paired with an AI diagnostic platform for home-based cardiometabolic assessment. It serves clinicians, cardiologists, and clinical research organizations by delivering continuous, clinical-grade remote diagnostic data covering cardiac, pulmonary, vascular, and hemodynamic systems.

0 investors

Sound World Solutions develops affordable, self-customizable personal sound amplifiers and hearing devices that users adjust via a free mobile app, targeting people for whom conventional hearing aids are too costly or unavailable. The company sells directly to consumers worldwide using consumer electronics components to keep prices low.

0 investors

Nascent Biotech develops proprietary human monoclonal antibodies and immunotherapy for cancer treatment, with a lead therapeutic asset (Pritumumab) validated in brain cancer patients. The company is pursuing novel targets with a broad pipeline of therapies and diagnostics, supported by platform drug delivery technology.

0 investors

Naveris develops and commercializes liquid biopsy tests for the early detection and monitoring of HPV-associated cancers, particularly head and neck and anal cancers. The company's flagship NavDx test uses proprietary technology to detect tumor tissue-modified viral HPV DNA in blood plasma, offering high sensitivity and specificity for cancer surveillance.

0 investors

Navrogen is a biopharmaceutical company developing therapeutic agents that counter tumor-produced Humoral Immuno-Oncology (HIO) factors linked to suppressed humoral immunity and poor response to immune-mediated anti-cancer therapies. It uses proprietary screening, antibody engineering technologies, and diagnostic assays to identify patients whose tumors produce HIO factors, targeting cancer and immune-related disorders.

0 investors

NED Biosystems develops patented, non-toxic combination cancer treatments using a systems biology approach targeting multiple disease pathways simultaneously. The company's lead program NED-170 is designed for late-stage cancer patients, particularly those who are heavily pre-treated, with a focus on achieving no evidence of disease while minimizing toxicity and side effects.

0 investors

NED Medical develops CombiSphere, a Y90 radioembolization therapy made with proprietary materials offering optimized particle size, density, radiopacity, and dosimetry to treat liver cancer. The product is aimed at clinicians treating oncology patients through embolization therapy.

0 investors

NeOnc is a biopharmaceutical company developing a patented platform technology to transport therapeutics across the blood-brain barrier, including intranasal delivery formulations such as NEO100 and NEO400. It targets brain and central nervous system diseases like glioblastoma and other brain cancers, serving patients and partnering with pharmaceutical companies.

0 investors

Neuro-Kinesis develops biosensor-integrated surgical instruments that deliver real-time biological feedback to surgeons during procedures. The company focuses on catheter-based imaging tools and neurosurgical retractors designed to improve procedural outcomes in cardiac mapping, organ visualization, and brain surgery.

0 investors

NeuroCytonix operates a clinical research center in Monterrey, Mexico that develops and conducts investigational protocols for neurological conditions including cerebral palsy, autism, stroke, and traumatic brain injury. The center is designed to provide personalized clinical care and research in compliance with international good clinical practice standards.

0 investors

Neuroelectrics develops the Starstim platform, combining EEG monitoring headpieces, cloud-based delivery, and personalized protocols to deliver non-invasive Transcranial Electrical Stimulation (tES) neuromodulation therapy for brain disorders such as depression and epilepsy. It serves patients whose conditions are not controlled by drugs or surgery, as well as neuroscience researchers who use its tools for brain research.

0 investors

NeuroEM Therapeutics develops MemorEM, a wearable head device that administers transcranial electromagnetic treatment to treat cognitive decline and Alzheimer's disease. The device targets patients with neurodegenerative diseases through a non-invasive, in-home treatment delivered by healthcare professionals.

0 investors

Neurolutions makes IpsiHand, an FDA-cleared brain-computer interface system for at-home motor rehabilitation of chronic stroke survivors with arm and hand weakness. The system pairs a non-invasive EEG headset, a thought-controlled wireless handpiece, and a tablet to guide and track therapy.

0 investors

NeuroNascent develops therapeutics aimed at generating new neurons and regenerating existing ones to treat neurological disorders. Its R&D pipeline targets conditions including Alzheimer's disease, Parkinson's disease, and developmental delay, alongside a veterinary medicine program.

0 investors

NMTC develops neurotechnology combining medical devices and artificial intelligence, supported by scientific and AI advisory boards. The company works with medical and neuroscience experts to advance its innovations.

0 investors

Neuropathix is a biopharmaceutical company developing patented cannabinoid-inspired molecules and therapeutics targeting inflammation for conditions including chemotherapy-induced peripheral neuropathy, hepatic encephalopathy, mild traumatic brain injury, and chronic pain. Its subsidiary Kannalife Sciences has licensed a U.S. government patent on cannabinoids as antioxidants and neuroprotectants, and its lead drug candidate KLS-13019 is a CBD-like new chemical entity.

0 investors

NeuroPro is developing NPT 2042, a drug candidate targeting epilepsy, with reported efficacy in pharmacology models comparable to NKCC antagonists such as bumetanide and furosemide. The compound has shown plasma exposure across species including humans and no negative safety signals in animals or humans to date.

0 investors